Spinal Muscular Atrophy Treatment Market Report 2026

The spinal muscular atrophy treatment market size has grown rapidly in recent years. It will grow from $5.1 billion in 2025 to $5.89 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to limited therapeutic options for sma, low awareness of genetic disorders, reliance on hospital-based treatment, slow adoption of innovative therapies, lack of early diagnosis programs.

The spinal muscular atrophy treatment market size is expected to see rapid growth in the next few years. It will grow to $10.38 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to development of advanced gene therapies, rising investment in sma research, increasing newborn screening initiatives, growth of specialty clinics and homecare services, integration of digital health and telemedicine solutions. Major trends in the forecast period include rising adoption of gene therapy and smn2 modifying treatments, increased focus on early diagnosis and newborn screening programs, growth in homecare and specialty clinic-based sma management, expansion of multidisciplinary care teams for sma patients, integration of telehealth and remote patient monitoring.

The increasing emphasis on gene therapy is expected to drive the growth of the spinal muscular atrophy (SMA) treatment market in the coming years. Gene therapy is a medical approach that involves modifying or replacing a patient’s genetic material, either DNA or RNA, to treat or prevent disease. The rising focus on gene therapy is largely due to its ability to address the underlying genetic causes of inherited disorders by correcting or compensating for faulty genes, offering the potential for long-term or even permanent therapeutic benefits compared to conventional treatments. Spinal muscular atrophy treatments are well suited to gene therapy approaches, such as onasemnogene abeparvovec (Zolgensma), which provides a one-time, targeted intervention by delivering a functional copy of the SMN1 gene, leading to significant improvements in motor function and quality of life for patients with SMA. For example, in January 2024, according to the American Society of Gene and Cell Therapy, a US-based professional organization, the number of gene therapies in Phase III clinical trials increased by 10% in the fourth quarter of 2023 compared to the previous quarter, marking the first increase since the third quarter of 2022. Therefore, the growing focus on gene therapy is fueling the growth of the spinal muscular atrophy treatment market.

Major companies operating in the spinal muscular atrophy treatment market are concentrating on the development of innovative formulations, such as survival motor neuron 2 (SMN2) splicing modifier tablets, to improve motor function and slow disease progression. SMN2 splicing modifier tablets are oral medications designed to modify the splicing of the SMN2 gene, enabling increased production of functional SMN protein that is essential for motor neuron survival. These therapies help treat SMA by boosting full-length SMN protein levels, thereby improving muscle function and slowing disease progression. For instance, in February 2025, Genentech, Inc., a US-based biotechnology company, received U.S. Food and Drug Administration approval for Evrysdi (risdiplam) tablets, the first non-invasive SMN2 splicing modifier tablet approved for the treatment of SMA. The tablet formulation offers efficacy and safety comparable to the existing oral solution, along with advantages such as room-temperature storage and easier administration for patients aged two years and older who weigh more than 44 pounds (20 kg), providing added convenience and flexibility in disease management.

In January 2024, Voyager Therapeutics Inc., a US-based biotechnology company, entered into a partnership with Novartis to advance gene therapies for neurological diseases. Through this collaboration, Voyager Therapeutics and Novartis aim to discover and develop novel gene therapies for conditions including Huntington’s disease and spinal muscular atrophy by combining Voyager’s TRACER capsid technology with Novartis’s expertise in gene therapy development and commercialization. Novartis is a Switzerland-based pharmaceutical company specializing in treatments for spinal muscular atrophy.

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED.

North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spinal muscular atrophy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the spinal muscular atrophy treatment market by increasing the cost of imported gene therapy drugs, biologics, and specialized medical equipment. Segments such as onasemnogene abeparvovec-xioi (zolgensma) and nusinersen (spinraza) are particularly affected, with North America and Europe experiencing higher costs due to import duties. While tariffs pose challenges in pricing and accessibility, they have also encouraged local manufacturing, regional partnerships, and investment in domestic production capabilities to improve supply chain resilience.

The spinal muscular atrophy treatment market research report is one of a series of new reports that provides spinal muscular atrophy treatment market statistics, including spinal muscular atrophy treatment industry global market size, regional shares, competitors with a spinal muscular atrophy treatment market share, detailed spinal muscular atrophy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the spinal muscular atrophy treatment industry. This spinal muscular atrophy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Spinal muscular atrophy (SMA) treatment involves medical therapies and interventions focused on managing symptoms, improving muscle strength and motor function, and enhancing the quality of life for individuals with spinal muscular atrophy. SMA is a genetic condition marked by the progressive degeneration of motor neurons in the spinal cord and lower brainstem.

The main treatment types for spinal muscular atrophy include medication, physical therapy, surgery, and other supportive approaches. Medications are used to control symptoms, improve motor function, and slow disease progression. These treatments address various forms of spinal muscular atrophy, including Werdnig-Hoffmann disease, infantile spinal muscular atrophy, Kugelberg-Welander disease, and adult-onset spinal muscular atrophy. Drugs are administered through different routes, such as oral and parenteral, and are distributed via hospital pharmacies, retail pharmacies, and other distribution channels. The key end users include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The spinal muscular atrophy treatment market consists of revenues earned by entities by providing services such as gene delivery services, diagnostic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The spinal muscular atrophy treatment market also includes sales of spinraza, zolgensma, evrysdi, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.